JP6871400B2 - 眼表面疾患の治療のための製剤および関連方法 - Google Patents
眼表面疾患の治療のための製剤および関連方法 Download PDFInfo
- Publication number
- JP6871400B2 JP6871400B2 JP2019546769A JP2019546769A JP6871400B2 JP 6871400 B2 JP6871400 B2 JP 6871400B2 JP 2019546769 A JP2019546769 A JP 2019546769A JP 2019546769 A JP2019546769 A JP 2019546769A JP 6871400 B2 JP6871400 B2 JP 6871400B2
- Authority
- JP
- Japan
- Prior art keywords
- preparation
- dry eye
- eye disease
- disease according
- treating dry
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000009472 formulation Methods 0.000 title claims description 46
- 239000000203 mixture Substances 0.000 title claims description 46
- 238000000034 method Methods 0.000 title description 7
- 208000003556 Dry Eye Syndromes Diseases 0.000 claims description 37
- JBDGDEWWOUBZPM-XYPYZODXSA-N ambroxol Chemical compound NC1=C(Br)C=C(Br)C=C1CN[C@@H]1CC[C@@H](O)CC1 JBDGDEWWOUBZPM-XYPYZODXSA-N 0.000 claims description 32
- 229960005174 ambroxol Drugs 0.000 claims description 28
- 238000002360 preparation method Methods 0.000 claims description 18
- 239000000654 additive Substances 0.000 claims description 9
- 229920000249 biocompatible polymer Polymers 0.000 claims description 8
- 239000012730 sustained-release form Substances 0.000 claims description 8
- 208000024891 symptom Diseases 0.000 claims description 7
- 210000000795 conjunctiva Anatomy 0.000 claims description 6
- 230000000699 topical effect Effects 0.000 claims description 6
- QNVKOSLOVOTXKF-UHFFFAOYSA-N 4-[(2-amino-3,5-dibromophenyl)methylamino]cyclohexan-1-ol;hydron;chloride Chemical compound Cl.NC1=C(Br)C=C(Br)C=C1CNC1CCC(O)CC1 QNVKOSLOVOTXKF-UHFFFAOYSA-N 0.000 claims description 5
- 239000000499 gel Substances 0.000 claims description 5
- 239000002674 ointment Substances 0.000 claims description 5
- 239000003755 preservative agent Substances 0.000 claims description 5
- 230000000996 additive effect Effects 0.000 claims description 4
- 229960000985 ambroxol hydrochloride Drugs 0.000 claims description 4
- 210000004087 cornea Anatomy 0.000 claims description 4
- 239000006196 drop Substances 0.000 claims description 4
- 239000006072 paste Substances 0.000 claims description 4
- 229920001610 polycaprolactone Polymers 0.000 claims description 4
- 239000004632 polycaprolactone Substances 0.000 claims description 4
- 150000003839 salts Chemical class 0.000 claims description 4
- 239000000243 solution Substances 0.000 claims description 4
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 239000002502 liposome Substances 0.000 claims description 3
- 239000004530 micro-emulsion Substances 0.000 claims description 3
- 239000002105 nanoparticle Substances 0.000 claims description 3
- 239000000725 suspension Substances 0.000 claims description 3
- 239000003826 tablet Substances 0.000 claims description 3
- -1 trans-4- (2-amino-3,5-dibromophenylamino) cyclohexanol hydrochloride Chemical compound 0.000 claims description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims description 2
- 102000008186 Collagen Human genes 0.000 claims description 2
- 108010035532 Collagen Proteins 0.000 claims description 2
- WOBHKFSMXKNTIM-UHFFFAOYSA-N Hydroxyethyl methacrylate Chemical compound CC(=C)C(=O)OCCO WOBHKFSMXKNTIM-UHFFFAOYSA-N 0.000 claims description 2
- 229920002153 Hydroxypropyl cellulose Polymers 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 229920001436 collagen Polymers 0.000 claims description 2
- 239000003974 emollient agent Substances 0.000 claims description 2
- 239000000017 hydrogel Substances 0.000 claims description 2
- 239000001863 hydroxypropyl cellulose Substances 0.000 claims description 2
- 235000010977 hydroxypropyl cellulose Nutrition 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000006210 lotion Substances 0.000 claims description 2
- 230000003232 mucoadhesive effect Effects 0.000 claims description 2
- 239000002245 particle Substances 0.000 claims description 2
- 239000008188 pellet Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000002504 physiological saline solution Substances 0.000 claims 1
- 230000002335 preservative effect Effects 0.000 claims 1
- 210000001508 eye Anatomy 0.000 description 15
- 239000000126 substance Chemical class 0.000 description 9
- 239000012528 membrane Substances 0.000 description 7
- 210000004379 membrane Anatomy 0.000 description 7
- 238000013268 sustained release Methods 0.000 description 6
- 210000005252 bulbus oculi Anatomy 0.000 description 5
- 102000010637 Aquaporins Human genes 0.000 description 4
- 239000003981 vehicle Substances 0.000 description 4
- 102000004392 Aquaporin 5 Human genes 0.000 description 3
- 108090000976 Aquaporin 5 Proteins 0.000 description 3
- 108010063290 Aquaporins Proteins 0.000 description 3
- 206010013774 Dry eye Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 102000009616 Mucin 5AC Human genes 0.000 description 3
- 108010034536 Mucin 5AC Proteins 0.000 description 3
- 238000013459 approach Methods 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 239000006185 dispersion Substances 0.000 description 3
- 239000003889 eye drop Substances 0.000 description 3
- 229940012356 eye drops Drugs 0.000 description 3
- 230000013632 homeostatic process Effects 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 208000023715 Ocular surface disease Diseases 0.000 description 2
- 208000003251 Pruritus Diseases 0.000 description 2
- 206010047513 Vision blurred Diseases 0.000 description 2
- OSASVXMJTNOKOY-UHFFFAOYSA-N chlorobutanol Chemical compound CC(C)(O)C(Cl)(Cl)Cl OSASVXMJTNOKOY-UHFFFAOYSA-N 0.000 description 2
- 230000001684 chronic effect Effects 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 208000035475 disorder Diseases 0.000 description 2
- 210000000744 eyelid Anatomy 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000007803 itching Effects 0.000 description 2
- 239000000314 lubricant Substances 0.000 description 2
- 210000003097 mucus Anatomy 0.000 description 2
- 230000003204 osmotic effect Effects 0.000 description 2
- 230000028327 secretion Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
- FZWBNHMXJMCXLU-UHFFFAOYSA-N 2,3,4,5-tetrahydroxy-6-[3,4,5-trihydroxy-6-[[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxyhexanal Chemical compound OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OCC(O)C(O)C(O)C(O)C=O)O1 FZWBNHMXJMCXLU-UHFFFAOYSA-N 0.000 description 1
- 102000004363 Aquaporin 3 Human genes 0.000 description 1
- 108090000991 Aquaporin 3 Proteins 0.000 description 1
- BTBUEUYNUDRHOZ-UHFFFAOYSA-N Borate Chemical compound [O-]B([O-])[O-] BTBUEUYNUDRHOZ-UHFFFAOYSA-N 0.000 description 1
- 206010006784 Burning sensation Diseases 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- 206010011224 Cough Diseases 0.000 description 1
- 206010013710 Drug interaction Diseases 0.000 description 1
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 description 1
- 239000004354 Hydroxyethyl cellulose Substances 0.000 description 1
- 239000004166 Lanolin Substances 0.000 description 1
- 208000010415 Low Vision Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 206010034972 Photosensitivity reaction Diseases 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 description 1
- 230000005856 abnormality Effects 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 210000001552 airway epithelial cell Anatomy 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 150000007514 bases Chemical class 0.000 description 1
- 229960000686 benzalkonium chloride Drugs 0.000 description 1
- CADWTSSKOVRVJC-UHFFFAOYSA-N benzyl(dimethyl)azanium;chloride Chemical compound [Cl-].C[NH+](C)CC1=CC=CC=C1 CADWTSSKOVRVJC-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 239000008112 carboxymethyl-cellulose Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 229960004926 chlorobutanol Drugs 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- UREBDLICKHMUKA-CXSFZGCWSA-N dexamethasone Chemical compound C1CC2=CC(=O)C=C[C@]2(C)[C@]2(F)[C@@H]1[C@@H]1C[C@@H](C)[C@@](C(=O)CO)(O)[C@@]1(C)C[C@@H]2O UREBDLICKHMUKA-CXSFZGCWSA-N 0.000 description 1
- 229960003957 dexamethasone Drugs 0.000 description 1
- 229940119743 dextran 70 Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 239000007938 effervescent tablet Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008020 evaporation Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 239000003172 expectorant agent Substances 0.000 description 1
- 238000013265 extended release Methods 0.000 description 1
- 229940014259 gelatin Drugs 0.000 description 1
- 235000011187 glycerol Nutrition 0.000 description 1
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 230000009545 invasion Effects 0.000 description 1
- 206010023332 keratitis Diseases 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 229940039717 lanolin Drugs 0.000 description 1
- 235000019388 lanolin Nutrition 0.000 description 1
- 230000007774 longterm Effects 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002900 methylcellulose Drugs 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229940066491 mucolytics Drugs 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 210000004400 mucous membrane Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000003208 petroleum Substances 0.000 description 1
- 201000003040 photosensitive epilepsy Diseases 0.000 description 1
- 230000036211 photosensitivity Effects 0.000 description 1
- 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
- 229940068918 polyethylene glycol 400 Drugs 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 229940068984 polyvinyl alcohol Drugs 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 201000005070 reflex epilepsy Diseases 0.000 description 1
- 230000036412 respiratory physiology Effects 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229910001415 sodium ion Inorganic materials 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 230000004489 tear production Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 230000032258 transport Effects 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 230000003827 upregulation Effects 0.000 description 1
- 239000001993 wax Substances 0.000 description 1
- 239000011701 zinc Substances 0.000 description 1
- 229910052725 zinc Inorganic materials 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/04—Artificial tears; Irrigation solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/10—Ophthalmic agents for accommodation disorders, e.g. myopia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
Description
Claims (16)
- 製剤の総重量または総容量に対し、0.01%から20%の間の重量パーセントのアンブロキソールおよび/または塩の形態のアンブロキソール、および、担体を含有し、
少なくとも1日1回、少なくとも5日の期間にわたって対象者に投与されることを特徴とするドライアイ疾患治療用製剤。 - 前記塩の形態のアンブロキソールが、塩酸アンブロキソールからなる、請求項1に記載のドライアイ疾患治療用製剤。
- 前記塩酸アンブロキソールが、製剤の総重量または総容量に対し、0.02%〜10%の間の重量パーセントで存在する、請求項2に記載のドライアイ疾患治療用製剤。
- 前記塩酸アンブロキソールが、製剤の総重量または総容量に対し、0.5%〜5%の間の重量パーセントで存在する、請求項2に記載のドライアイ疾患治療用製剤。
- 前記塩の形態のアンブロキソールが、トランス‐4‐(2‐アミノ‐3,5‐ジブロモフェニルアミノ)シクロヘキサノール塩酸塩からなる、請求項1に記載のドライアイ疾患治療用製剤。
- 前記担体が、眼への局所適用に適した担体である、請求項1〜5のいずれか1つに記載のドライアイ疾患治療用製剤。
- 前記担体が、緩衝生理食塩溶液からなる、請求項6に記載のドライアイ疾患治療用製剤。
- 前記担体に溶解された生体適合性ポリマー、または生体適合性ポリマー内に含浸されたアンブロキソールをさらに含む、請求項1〜7のいずれか1つに記載のドライアイ疾患治療用製剤。
- 前記生体適合性ポリマーが、ポリ‐2‐ヒドロキシエチルメタクリレート(p‐HEMAヒドロゲル)、ポリ(乳酸‐コ‐グリコール)酸(PLGA)、ポリカプロラクトン(PCL)、ヒドロキシプロピルセルロース、酢酸アネコルタブ(AnA)、ゼラチン、および/またはコラーゲンである、請求項8に記載のドライアイ疾患治療用製剤。
- 少なくとも1つの添加剤をさらに含み、該添加剤は、緩和剤、保存剤、皮膚軟化剤、イオン種、pH調整剤、および他の添加剤である、請求項8に記載のドライアイ疾患治療用製剤。
- 製剤の連続適用を提供する装置を用いて対象者に投与される、請求項1〜10のいずれか1つに記載のドライアイ疾患治療用製剤。
- 前記対象者が、ドライアイ疾患の症状の一部または全部の軽減を経験する、請求項1〜10のいずれか1つに記載のドライアイ疾患治療用製剤。
- 少なくとも1日1回の頻度で、少なくとも1週間、1ヶ月および6ヶ月からなる群より選択される期間にわたって適用される、請求項1〜10のいずれか1つに記載のドライアイ疾患治療用製剤。
- 溶液、ゲル、滴剤、軟膏、懸濁液、マイクロエマルジョン、ナノ粒子、リポソーム、ローション、またはペーストの形態で投与される、請求項1〜10のいずれか1つに記載のドライアイ疾患治療用製剤。
- 徐放性形態で投与される、請求項1〜10のいずれか1つに記載のドライアイ疾患治療用製剤。
- 徐放性形態を含み、外部ポンプ、コンタクトレンズ、涙点プラグ、粘膜付着性錠剤、ピル、カプセル、ペレット、粒子、プラスターもしくは結膜または角膜上に配置される細片、または結膜挿入物もしくはデポ、結膜下、テノン嚢下または硝子体内注射、挿入物もしくはデポを用いて投与される、請求項15に記載のドライアイ疾患治療用製剤。
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662421822P | 2016-11-14 | 2016-11-14 | |
US62/421,822 | 2016-11-14 | ||
US201762463717P | 2017-02-26 | 2017-02-26 | |
US62/463,717 | 2017-02-26 | ||
PCT/US2017/061108 WO2018089797A1 (en) | 2016-11-14 | 2017-11-10 | Formulations for the treatment of ocular surface diseases and related methods |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2019534335A JP2019534335A (ja) | 2019-11-28 |
JP2019534335A5 JP2019534335A5 (ja) | 2020-01-16 |
JP6871400B2 true JP6871400B2 (ja) | 2021-05-12 |
Family
ID=62107036
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019546769A Active JP6871400B2 (ja) | 2016-11-14 | 2017-11-10 | 眼表面疾患の治療のための製剤および関連方法 |
Country Status (8)
Country | Link |
---|---|
US (4) | US10265280B2 (ja) |
EP (1) | EP3538083A4 (ja) |
JP (1) | JP6871400B2 (ja) |
KR (1) | KR102116303B1 (ja) |
CN (2) | CN109982692A (ja) |
AU (1) | AU2017357755B2 (ja) |
CA (1) | CA3043327C (ja) |
WO (1) | WO2018089797A1 (ja) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN108969511A (zh) * | 2018-07-12 | 2018-12-11 | 图桑医疗科技(深圳)有限公司 | 溴已新及其衍生物在治疗和预防眼表疾病上的应用 |
WO2023230430A1 (en) * | 2022-05-21 | 2023-11-30 | Neuvision Development Llc | Topical ocular administration of ambroxol for ocular pain |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU574360B2 (en) | 1983-05-13 | 1988-07-07 | Reichert, D. | Antisnoring agent |
DE3610997A1 (de) | 1986-04-02 | 1987-10-15 | Krewel Werke Gmbh | Ambroxol-nasenspray |
DE3731528A1 (de) * | 1987-09-18 | 1989-04-13 | Krewel Werke Gmbh | Verwendung von trans-4- ((2-amino-3,5-dibrom-benzyl)-amino) -cyclohexanol zur lokalen behandlung von erkrankungen des auges |
CA2161217A1 (en) | 1993-04-30 | 1994-11-10 | Carmelita Macklin Russell | Coated pharmaceutical compositions |
US5458879A (en) | 1994-03-03 | 1995-10-17 | The Procter & Gamble Company | Oral vehicle compositions |
IT1303671B1 (it) | 1998-07-28 | 2001-02-23 | Nicox Sa | Sali dell'acido nitrico con farmaci attivi nel trattamento dipatologie del sistema respiratorio |
DE69825495T2 (de) | 1998-12-23 | 2005-07-28 | Idea Ag | Verbesserte formulierung zur topischen, nichtinvasiven anwendung in vivo |
DE19933148A1 (de) | 1999-07-20 | 2001-01-25 | Boehringer Ingelheim Int | Ambroxolhaltige Lutschtablette |
US7179849B2 (en) | 1999-12-15 | 2007-02-20 | C. R. Bard, Inc. | Antimicrobial compositions containing colloids of oligodynamic metals |
KR100740056B1 (ko) | 2000-03-07 | 2007-07-16 | 데이진 가부시키가이샤 | 신축성 첩부제 |
US20030216423A1 (en) | 2000-05-24 | 2003-11-20 | Sergio Ulloa | Stable liquid and solid formulations |
ITRM20010438A1 (it) * | 2001-07-23 | 2003-01-23 | Farmigea Spa | Preparato oftalmico a base di n-acetilcisteina per il trattamento della sindrome dell'occhio secco. |
DE10140320A1 (de) | 2001-08-16 | 2003-03-06 | Udo Zirfas | Potenzfördernder und vitaltonisierender Wirkstoff |
US20030171391A1 (en) | 2002-01-25 | 2003-09-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of chronic pain |
DE10203104A1 (de) | 2002-01-25 | 2003-08-07 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung chronischer Schmerzen |
US20030166732A1 (en) | 2002-02-27 | 2003-09-04 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol for the treatment of painful conditions in the mouth and pharyngeal cavity |
DE10208313A1 (de) | 2002-02-27 | 2003-09-11 | Boehringer Ingelheim Pharma | Ambroxol für die Behandlung von schmerzhaften Zuständen im Mund und Rachenraum |
JP2004175749A (ja) * | 2002-11-28 | 2004-06-24 | Senju Pharmaceut Co Ltd | ドライアイおよびドライアイを伴う疾病の治療剤 |
DE10332473A1 (de) | 2003-07-16 | 2005-02-03 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von Epilepsie |
DE10332487A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung von chronisch nozizeptiven Schmerzen |
DE10332486A1 (de) | 2003-07-16 | 2005-02-10 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Ambroxol für die Behandlung akuter Schmerzen |
AU2003904192A0 (en) * | 2003-08-11 | 2003-08-21 | Adelaide Research and Innovaiton Pty Ltd | Method for inhibiting bacterial colonisation |
KR20050036166A (ko) * | 2003-10-15 | 2005-04-20 | 베링거 잉겔하임 파르마 게엠베하 운트 코 카게 | 인두내 염증 치료용 암브록솔 |
US9016221B2 (en) | 2004-02-17 | 2015-04-28 | University Of Florida Research Foundation, Inc. | Surface topographies for non-toxic bioadhesion control |
DE102004021992A1 (de) | 2004-05-03 | 2005-11-24 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Topische Zubereitung enthaltend Ambroxol |
US20070014833A1 (en) * | 2005-03-30 | 2007-01-18 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
AU2006249816A1 (en) * | 2005-05-25 | 2006-11-30 | Sirtris Pharmaceuticals, Inc. | Treatment of eye disorders with sirtuin modulators |
JP5337405B2 (ja) | 2007-09-17 | 2013-11-06 | ザ・ホスピタル・フォー・シック・チルドレン | ゴーシェ病の治療方法 |
GB0801876D0 (en) | 2008-02-01 | 2008-03-12 | Vectura Group Plc | Suspension formulations |
US8784870B2 (en) | 2008-07-21 | 2014-07-22 | Otonomy, Inc. | Controlled release compositions for modulating free-radical induced damage and methods of use thereof |
GB0921481D0 (en) | 2009-12-08 | 2010-01-20 | Vectura Ltd | Process and product |
EP2538929A4 (en) * | 2010-02-25 | 2014-07-09 | Univ Johns Hopkins | PROLONGED DELIVERY OF THERAPEUTIC AGENTS TO AN OCULAR COMPARTMENT |
AU2012359165A1 (en) * | 2011-12-22 | 2014-07-10 | Centogene Ip Gmbh | Combination of a compound having the ability to rearrange a lysosomal enzyme and ambroxol and/or a derivative of ambroxol |
CN102670607A (zh) | 2012-05-28 | 2012-09-19 | 海南卫康制药(潜山)有限公司 | 复方盐酸氨溴索组合物及其制备方法 |
WO2014127007A1 (en) * | 2013-02-12 | 2014-08-21 | Seryx Biomedical, Inc. | Ophthalmic formulation derived from silk protein |
HU231191B1 (hu) | 2013-04-15 | 2021-08-30 | Szegedi Tudományegyetem | Izotóp tartalmú morfin molekulák |
JP6596421B2 (ja) | 2013-08-23 | 2019-10-23 | パリオン・サイエンシィズ・インコーポレーテッド | ジチオール粘液溶解薬 |
-
2017
- 2017-11-10 AU AU2017357755A patent/AU2017357755B2/en active Active
- 2017-11-10 KR KR1020197016988A patent/KR102116303B1/ko active IP Right Grant
- 2017-11-10 CN CN201780070126.8A patent/CN109982692A/zh active Pending
- 2017-11-10 CA CA3043327A patent/CA3043327C/en active Active
- 2017-11-10 CN CN202210992714.XA patent/CN115607531A/zh active Pending
- 2017-11-10 US US15/809,659 patent/US10265280B2/en active Active
- 2017-11-10 JP JP2019546769A patent/JP6871400B2/ja active Active
- 2017-11-10 EP EP17868628.3A patent/EP3538083A4/en active Pending
- 2017-11-10 WO PCT/US2017/061108 patent/WO2018089797A1/en active Application Filing
-
2019
- 2019-03-19 US US16/358,517 patent/US20190209496A1/en not_active Abandoned
-
2020
- 2020-11-02 US US17/087,504 patent/US20210046022A1/en not_active Abandoned
-
2022
- 2022-07-28 US US17/875,871 patent/US20220378723A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
WO2018089797A1 (en) | 2018-05-17 |
US20190209496A1 (en) | 2019-07-11 |
AU2017357755A1 (en) | 2019-05-30 |
KR20190085038A (ko) | 2019-07-17 |
US20210046022A1 (en) | 2021-02-18 |
AU2017357755B2 (en) | 2019-06-13 |
KR102116303B1 (ko) | 2020-05-29 |
CN115607531A (zh) | 2023-01-17 |
EP3538083A1 (en) | 2019-09-18 |
US10265280B2 (en) | 2019-04-23 |
CN109982692A (zh) | 2019-07-05 |
US20180133173A1 (en) | 2018-05-17 |
CA3043327A1 (en) | 2018-05-17 |
US20220378723A1 (en) | 2022-12-01 |
CA3043327C (en) | 2020-08-11 |
EP3538083A4 (en) | 2020-05-27 |
JP2019534335A (ja) | 2019-11-28 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US9925201B2 (en) | Compositions and treatment for eye diseases and disorders | |
US20220378723A1 (en) | Formulations for the treatment of ocular surface diseases and related methods | |
DE60315258T2 (de) | Behandlung von nicht-schmerzhaften blasenstörungen mit modulatoren der alpha-2-delta-untereinheit des calciumkanals | |
JP2019534335A5 (ja) | ||
CN112915090A (zh) | 用于治疗眼表疾病的一类化合物及其相关制剂和应用方法 | |
TWI805705B (zh) | 選擇性syk抑制劑之使用方法及醫藥組合物 | |
JP7038448B1 (ja) | 抗アレルギー用投与デバイス | |
CN105214092B (zh) | 重组人白细胞介素-1受体拮抗剂及其组合物及药物用途 | |
TWI632913B (zh) | 用於眼部疾病或異常之組合物及其治療方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190702 Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190705 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190702 |
|
A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200624 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200630 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20200923 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20201106 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210323 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210415 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 6871400 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |